Oxymetazoline Hydrochloride (Cream) interactions
Checked as Oxymetazoline (topical) in this data source.
Full monograph for Oxymetazoline Hydrochloride (Cream)Check it against another medicine
Medicines
36 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Ergometrine Maleate | Major | Synergy | Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central… | 38 sources — open the full entry |
| Methylergonovine Maleate | Major | Synergy | Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central… | 38 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Arformoterol Tartrate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Bupropion Hydrochloride | Moderate | Synergy | Translated with DeepL | 4 sources — open the full entry |
| Desvenlafaxine Succinate | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Dextromethorphan + Bupropion | Moderate | Synergy | Translated with DeepL | 4 sources — open the full entry |
| Duloxetine Hydrochloride | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Fluticasone Propionate + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Formoterol Fumarate + Glycopyrrolate + Budesonide | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Indacaterol + Glycopyrronium | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Indacaterol + Glycopyrronium + Mometasone Furoate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Indacaterol Maleate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Ketamine Hydrochloride | Moderate | Synergy | Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index… | 7 sources — open the full entry |
| Levomilnacipran Hydrochloride | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| LevosalbutamolOralRespirator preparation | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Linezolid | Moderate | Synergy | By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically… | 34 sources — open the full entry |
| Milnacipran Hydrochloride | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Mometasone Furoate + Formoterol Fumarate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Racepinephrine | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Rasagiline | Moderate | Synergy | By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically… | 34 sources — open the full entry |
| Ritodrine Hydrochloride | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Safinamide Mesylate | Moderate | Metabolism | Monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of sympathomimetic agents following oral and/or topical… | 20 sources — open the full entry |
| SalbutamolbaseInhaler | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Salbutamol + Budesonide | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Salbutamol + IpratropiumInhalerSolution for inhalation | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Salmeterol + Fluticasone Propionate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Salmeterol Xinafoate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Tapentadol Hydrochloride | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Terbutaline Sulfate | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Venlafaxine Hydrochloride | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
This source documents no food, condition or duplication entries for Oxymetazoline Hydrochloride (Cream).